Compare Quest Diagnostics Inc (DGX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Annaly Capital Management, Inc. — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Annaly Capital Management, Inc. trades at $18.31 (market cap $13.77B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Annaly Capital Management, Inc. for 91 Days on average.
| DGX | NLY | |
|---|---|---|
Market Cap | $25.48B | $13.77B |
Volume | 941,866 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $247.45 | $24.40 |
52-Week Low | $173.49 | $17.93 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $31.23B | $135.80B |
Dividend Yield | 1.49% | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
NLY trades at $18.30, up 2.06% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows strong profitability with a 92.77% net income margin and a low P/E of 4.41. Recent earnings have consistently beaten estimates, and the company maintains a high dividend yield near 15%, supported by a $0.75 quarterly payout announced for Q3 2026.
The outlook is mixed: attractive valuation and high yield offer upside potential, but significant cash flow volatility and rising debt-to-asset ratio pose risks. Analyst consensus is bullish with a $22.00 price target, yet technical weakness and interest rate sensitivity warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
